Headlands Technologies LLC Has $98,000 Stock Holdings in Arvinas, Inc. (NASDAQ:ARVN)

Headlands Technologies LLC increased its holdings in shares of Arvinas, Inc. (NASDAQ:ARVN) by 393.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,388 shares of the company’s stock after buying an additional 1,904 shares during the quarter. Headlands Technologies LLC’s holdings in Arvinas were worth $98,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently bought and sold shares of the company. FMR LLC raised its holdings in shares of Arvinas by 10.6% during the 3rd quarter. FMR LLC now owns 4,868,295 shares of the company’s stock valued at $95,613,000 after purchasing an additional 466,667 shares in the last quarter. Vanguard Group Inc. increased its position in Arvinas by 2.0% during the third quarter. Vanguard Group Inc. now owns 4,608,223 shares of the company’s stock worth $90,505,000 after buying an additional 90,426 shares during the last quarter. Charles Schwab Investment Management Inc. raised its holdings in Arvinas by 18.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 429,990 shares of the company’s stock valued at $8,445,000 after buying an additional 66,430 shares in the last quarter. Algert Global LLC lifted its position in shares of Arvinas by 45.5% in the third quarter. Algert Global LLC now owns 173,418 shares of the company’s stock worth $3,406,000 after buying an additional 54,229 shares during the last quarter. Finally, Federated Hermes Inc. boosted its stake in shares of Arvinas by 32.4% during the 4th quarter. Federated Hermes Inc. now owns 138,028 shares of the company’s stock worth $5,681,000 after acquiring an additional 33,770 shares in the last quarter. 95.19% of the stock is owned by institutional investors and hedge funds.

Arvinas Stock Performance

NASDAQ:ARVN opened at $31.90 on Tuesday. The company has a market capitalization of $2.18 billion, a price-to-earnings ratio of -4.91 and a beta of 1.94. The company has a 50-day moving average of $41.53 and a 200-day moving average of $34.76. Arvinas, Inc. has a 52 week low of $13.57 and a 52 week high of $53.08.

Arvinas (NASDAQ:ARVN) last announced its quarterly earnings results on Tuesday, February 27th. The company reported ($2.53) EPS for the quarter, missing analysts’ consensus estimates of ($1.15) by ($1.38). Arvinas had a negative return on equity of 70.24% and a negative net margin of 185.09%. The business had revenue of ($43.10) million for the quarter, compared to the consensus estimate of $38.91 million. During the same quarter in the prior year, the business earned ($1.56) EPS. Sell-side analysts forecast that Arvinas, Inc. will post -5.02 EPS for the current year.

Insider Transactions at Arvinas

In other Arvinas news, CFO Sean A. Cassidy sold 1,702 shares of the company’s stock in a transaction on Friday, February 23rd. The stock was sold at an average price of $47.05, for a total value of $80,079.10. Following the sale, the chief financial officer now directly owns 181,916 shares in the company, valued at $8,559,147.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, insider Ronald Peck sold 1,699 shares of the firm’s stock in a transaction that occurred on Friday, February 23rd. The shares were sold at an average price of $47.05, for a total transaction of $79,937.95. Following the completion of the sale, the insider now owns 67,516 shares of the company’s stock, valued at $3,176,627.80. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Sean A. Cassidy sold 1,702 shares of the business’s stock in a transaction that occurred on Friday, February 23rd. The stock was sold at an average price of $47.05, for a total value of $80,079.10. Following the completion of the transaction, the chief financial officer now directly owns 181,916 shares in the company, valued at $8,559,147.80. The disclosure for this sale can be found here. In the last ninety days, insiders sold 8,597 shares of company stock valued at $404,489. Corporate insiders own 5.23% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently issued reports on the stock. Leerink Partnrs reiterated an “outperform” rating on shares of Arvinas in a research note on Thursday, February 22nd. Truist Financial reaffirmed a “buy” rating and issued a $65.00 target price on shares of Arvinas in a report on Monday, March 25th. Oppenheimer reiterated an “outperform” rating and set a $80.00 price target (down from $95.00) on shares of Arvinas in a report on Wednesday, February 28th. Citigroup cut Arvinas from a “buy” rating to a “neutral” rating and increased their price objective for the company from $36.00 to $55.00 in a research report on Wednesday, February 14th. Finally, BMO Capital Markets boosted their target price on shares of Arvinas from $89.00 to $90.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 28th. Two investment analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. According to MarketBeat.com, Arvinas has an average rating of “Moderate Buy” and a consensus price target of $59.73.

Arvinas Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.